Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
- Study Type:
- EXPANDED_ACCESS
- Last Updated:
- 2026-08-06
Conditions
- Non Small Cell Lung Cancer
- ALK-positive Non-small Cell Lung Cancer (NSCLC)
Interventions
- DRUG
No Results Yet